What is Leerink Partnrs’ Forecast for FULC FY2027 Earnings?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Research analysts at Leerink Partnrs dropped their FY2027 EPS estimates for shares of Fulcrum Therapeutics in a research report issued on Monday, October 20th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($1.42) per share for the year, down from their previous forecast of ($1.36). The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Fulcrum Therapeutics in a research note on Monday. Wall Street Zen raised shares of Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 26th. Royal Bank Of Canada lifted their target price on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a “sector perform” rating in a report on Wednesday, July 30th. Finally, Leerink Partners set a $20.00 price target on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.20.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock opened at $9.04 on Thursday. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $9.89. The firm’s 50-day moving average is $7.84 and its two-hundred day moving average is $6.67. The stock has a market cap of $488.97 million, a price-to-earnings ratio of -7.41 and a beta of 2.93.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC boosted its stake in Fulcrum Therapeutics by 0.9% during the first quarter. Nantahala Capital Management LLC now owns 4,822,693 shares of the company’s stock worth $13,889,000 after buying an additional 42,985 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in Fulcrum Therapeutics by 53.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after buying an additional 1,589,000 shares during the period. Balyasny Asset Management L.P. purchased a new position in Fulcrum Therapeutics during the second quarter worth about $9,207,000. Exome Asset Management LLC boosted its stake in Fulcrum Therapeutics by 143.0% during the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock worth $1,985,000 after buying an additional 405,538 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of Fulcrum Therapeutics by 63.5% during the second quarter. Acadian Asset Management LLC now owns 563,380 shares of the company’s stock worth $3,871,000 after purchasing an additional 218,819 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.